logo

For the Inventor, By the Inventor

Nara, Japan

Takashi Sasatani

This inventor holds 11 USPTO granted patents, plus 1 CIPO patent. Top assignee: Shionogi Company Limited. Active years: 1980-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takashi Sasatani. Retrieved from https://idiyas.com/inventor/takashi-sasatani

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11

% Patents Active = 81.8


Average Co-Inventor Count = 3.6

ph-index = 6

Forward Citations = 149(Granted Patents)


Location History:

  • Sakai, JP (1980 - 1981)
  • Nara, JP (1987 - 1995)
  • Osaka, JP (2005 - 2013)

Company Filing History:

goldMedal11 out of 1,001 
 
Shionogi Company Limited
 patents

Years Active: 1980-2013

Loading Chart...
Loading Chart...
11 patents (USPTO):Explore Patents
1. 8367666 - 3-carbamoyl-2-pyridone derivatives (2013-02-05),
2. 6858640 - Tricyclic indole compounds having affinity for serotonin receptor (2005-02-22),
3. 5461062 - Condensed imidazopyridine derivatives (1995-10-24),
4. 5378848 - Condensed imidazopyridine derivatives (1995-01-03),
5. 4940714 - 2-substituted carbonylimidazo[4,5-c]quinolines (1990-07-10),
6. 4910318 - Tetrahydrothiopyrano(3,2-b)-indole derivatives (1990-03-20),
7. 4753951 - Condensed imidazopyridine derivatives useful as psychotropic agents (1988-06-28),
8. 4690930 - Pyrazolo[4,3-c]quinoline-3-one and imidazo[4,3-c]cinnolin-3-one (1987-09-01),
9. 4256640 - Tetrahydrothiopyrano[2,3-b]indole derivatives (1981-03-17),
10. 4200757 - Process for the production of 3-aminoisoxazoles (1980-04-29),
11. 4183856 - Process for the production of urea derivatives (1980-01-15),

Title: The Innovative Contributions of Takashi Sasatani

Introduction

Takashi Sasatani is a prominent inventor based in Nara, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target various receptors in the human body. With a total of 11 patents to his name, Sasatani's work has the potential to impact the treatment of several medical conditions.

Latest Patents

One of Sasatani's latest patents involves 3-carbamoyl-2-pyridone derivatives. This invention provides compounds that exhibit agonistic activity to the cannabinoid receptor. The patent outlines pharmaceutical compositions, atopic dermatitis treating agents, and anti-pruritus agents, especially those intended for oral use and external application. These compounds serve as active ingredients in addressing various health issues.

Another notable patent from Sasatani includes tricyclic indole compounds that have an affinity for serotonin receptors. These compounds are useful as therapeutic agents against various diseases of the central nervous system. The detailed chemical structures and functionalities of these compounds highlight their potential in medical applications.

Career Highlights

Sasatani is currently associated with Shionogi & Company Limited, a well-respected pharmaceutical company. His work at Shionogi has allowed him to focus on innovative research and development in the pharmaceutical sector. His contributions have been instrumental in advancing the company's portfolio of therapeutic agents.

Collaborations

Throughout his career, Sasatani has collaborated with notable colleagues, including Susumu Takada and Akira Matsushita. These collaborations have fostered a productive environment for innovation and have led to the successful development of various pharmaceutical compounds.

Conclusion

Takashi Sasatani's innovative work in the field of pharmaceuticals demonstrates his commitment to advancing medical science. His patents reflect a deep understanding of complex biochemical interactions and hold promise for future therapeutic applications.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…